This Article Full Text Full Text (PDF) An erratum has been published Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Starkey, C. R. Articles by Levy, L. S. Search for Related Content PubMed PubMed Citation Articles by Starkey, C. R. Articles by Levy, L. S.

 Previous Article  |  Next Article 

J Virol, February 1998, p. 1078-1084, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Tumorigenic Potential of a Recombinant Retrovirus Containing Sequences from Moloney Murine Leukemia Virus and Feline Leukemia Virus

C. R. Starkey,¹ P. A. Lobelle-Rich,¹ S. Granger,² B. K. Brightman,² H. Fan,² and L. S. Levy^1,*

Department of Microbiology and Immunology and Tulane Cancer Center, Tulane Medical School, New Orleans, Louisiana 70112,¹ and Department of Molecular Biology and Biochemistry and Cancer Research Institute, University of California, Irvine, California 92697²

Received 3 July 1997/Accepted 5 November 1997

A recombinant retrovirus, termed MoFe2-MuLV, was constructed in which the U3 region of T-lymphomagenic Moloney murine leukemia virus (Mo-MuLV) was replaced by that of FeLV-945, a provirus of unique long terminal repeat (LTR) structure identified only in non-T-cell, non-B-cell lymphomas of the domestic cat. The LTR of FeLV-945 is unusual in that it contains only a single copy of the transcriptional enhancer followed 25 bp downstream by a 21-bp sequence in triplicate in tandem. Infectivity of MoFe2-MuLV was demonstrated in vitro in SC-1 cells and in vivo in neonatal NIH-Swiss mice. Tumors occurred in MoFe2-MuLV-infected animals following a latency period of 4 to 10 months (average, 6 months). The results of Southern blot analysis of the T-cell receptor beta locus demonstrated that all tumors were lymphomas of T-cell origin. MoFe2-MuLV LTRs were amplified by PCR from tumor DNA and were characterized by nucleotide sequence analysis. LTRs from the tumors that occurred with relatively shorter latency predominantly retained the original MoFe2-MuLV sequence intact and unaltered. Tumors that occurred with relatively longer latency contained LTRs that also retained the 21-bp sequence triplication characteristic of the original virus but had acquired various duplications of enhancer sequences. The repeated identification of enhancer duplications in late-appearing tumors suggests that the duplication affords a selective advantage, although apparently not in the efficient induction of T-cell lymphoma. Proto-oncogenes known to be targets of insertional mutagenesis in the majority of Mo-MuLV-induced tumors or in feline non-T-cell, non-B-cell lymphomas were shown not to be rearranged in any tumor examined. Mink cell focus-inducing (MCF) proviral DNA was readily detectable in some, but not all, tumors. The presence or absence of MCF did not correlate with the kinetics of tumor induction. These studies indicate that the single-enhancer, triplication-containing FeLV LTR, typical of non-T-cell, non-B-cell lymphomas in cats, is competent in the induction of T-cell lymphoma in mice. The findings suggest that the mechanism of MoFe2-MuLV-mediated lymphomagenesis may differ from that of Mo-MuLV-mediated disease, considering the possible involvement of novel oncogenes and the variable presence of MCF recombinants.

---

^* Corresponding author. Mailing address: Department of Microbiology and Immunology, Tulane Medical School SL38, 1430 Tulane Ave., New Orleans, LA 70112. Phone: (504) 587-2083. Fax: (504) 588-5144. E-mail: llevy{at}tmcpop.tmc.tulane.edu.

This article has been cited by other articles:

• Finstad, S. L., Rosenberg, N., Levy, L. S. (2007). Diminished Potential for B-Lymphoid Differentiation after Murine Leukemia Virus Infection In Vivo and in EML Hematopoietic Progenitor Cells. J. Virol. 81: 7274-7279 [Abstract] [Full Text]  
• Johnson, C., Lobelle-Rich, P. A., Puetter, A., Levy, L. S. (2005). Substitution of Feline Leukemia Virus Long Terminal Repeat Sequences into Murine Leukemia Virus Alters the Pattern of Insertional Activation and Identifies New Common Insertion Sites. J. Virol. 79: 57-66 [Abstract] [Full Text]  
• Chandhasin, C., Lobelle-Rich, P., Levy, L. S. (2004). Feline leukaemia virus LTR variation and disease association in a geographical and temporal cluster. J. Gen. Virol. 85: 2937-2942 [Abstract] [Full Text]  
• Nishigaki, K., Hanson, C., Thompson, D., Yugawa, T., Hisasue, M., Tsujimoto, H., Ruscetti, S. (2002). Analysis of the Disease Potential of a Recombinant Retrovirus Containing Friend Murine Leukemia Virus Sequences and a Unique Long Terminal Repeat from Feline Leukemia Virus. J. Virol. 76: 1527-1532 [Abstract] [Full Text]  
• Merezak, C., Pierreux, C., Adam, E., Lemaigre, F., Rousseau, G. G., Calomme, C., Van Lint, C., Christophe, D., Kerkhofs, P., Burny, A., Kettmann, R., Willems, L. (2001). Suboptimal Enhancer Sequences Are Required for Efficient Bovine Leukemia Virus Propagation In Vivo: Implications for Viral Latency. J. Virol. 75: 6977-6988 [Abstract] [Full Text]  
• Ghosh, S. K., Roy-Burman, P., Faller, D. V. (2000). Long Terminal Repeat Regions from Exogenous but Not Endogenous Feline Leukemia Viruses Transactivate Cellular Gene Expression. J. Virol. 74: 9742-9748 [Abstract] [Full Text]  
• Granger, S. W., Bundy, L. M., Fan, H. (1999). Tandemization of a Subregion of the Enhancer Sequences from SRS 19-6 Murine Leukemia Virus Associated with T-Lymphoid but Not Other Leukemias. J. Virol. 73: 7175-7184 [Abstract] [Full Text]  
• Ghosh, S. K., Faller, D. V. (1999). Feline Leukemia Virus Long Terminal Repeat Activates Collagenase IV Gene Expression through AP-1. J. Virol. 73: 4931-4940 [Abstract] [Full Text]